NDA 022399 · Azurity
Horizant
Gabapentin Enacarbil · Oral
NovelOrphanLast checked: Nov 20, 2026Latest source record: Apr 25, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2011
Apr 6, 2011
Approved uses
3
Original approval plus efficacy supplements
Registered trials
501
111 Phase 3, 25 recruiting
FAERS reports
2,844
1,590 serious, 700 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 28, 2025.
HORIZANT is indicated for: treatment of moderate-to-severe primary Restless Legs Syndrome (RLS) in adults. ( 1.1 ) management of postherpetic neuralgia (PHN) in adults. ( 1.2 ) 1.1 Treatment of Restless Legs Syndrome HORIZANT ® is indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS) in adults. HORIZANT is not recommended for patients who are required to sleep during the daytime and remain awake at night. 1.2 Management of Postherpetic Neuralgia HORIZANT is indicated for the management of postherpetic neuralgia (PHN) in adults.
Mechanism: Gabapentin enacarbil is a prodrug of gabapentin and, accordingly, its therapeutic effects in RLS and PHN are attributable to gabapentin. The precise mechanism by which gabapentin is efficacious in RLS and PHN is unknown. The mechanism of action by which gabapentin is efficacious in PHN is unknown but in animal models of analgesia, gabapentin prevents allodynia (pain-related behavior in response to a normally innocuous stimulus) and hyperalgesia (exaggerated response to painful stimuli). Gabapentin prevents pain-related responses in several models of neuropathic pain in rats and mice (e.g.,...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 27, 2013 Supplement 5 · Efficacy ReviewLetterLabel
- Jun 6, 2012 Supplement 3 · Efficacy ReviewLabelLetter
- Apr 6, 2011 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelSummary ReviewLetter
2 products under this application
- HORIZANT · GABAPENTIN ENACARBIL 600MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
- HORIZANT · GABAPENTIN ENACARBIL 300MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Gabapentin Enacarbil" as an intervention, any sponsor and status, largest first.
- A Study of the Safety of Gabapentin in a Potential Over-the-Counter Population With Occasional SleeplessnessPivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT00666575 · 2,105 participants (planned) · Start Dec 2004
Drug: Gabapentin; Placebo · For: Transient Insomnia
Sites: Mobile, Alabama; Phoenix, Arizona; Beverly Hills, California · 23 sites in all
- MAST Trial: Multi-modal Analgesic Strategies in TraumaPivotal-lookingCompleted
The University of Texas Health Science Center, HoustonAcademic, hospital or other
NCT03472469 · 1,561 participants · Start Apr 2, 2018 · Primary completion Jul 3, 2019
Drug: Acetaminophen IV/PO; Acetaminophen PO and 9 more · For: Nonspecific Pain Post Traumatic Injury
Sites: Houston, Texas
- Determining the Effect of an "Alternate Recovery Protocol" Versus Current Standard of Care After Cesarean SectionPivotal-lookingTerminated
Brest, Norman A., M.D.Academic, hospital or other
NCT03330119 · 1,494 participants · Start Oct 4, 2017 · Primary completion Jun 20, 2018
Drug: Alternate Management; Control · For: Pregnancy Related; Narcotic Use
Sites: Wynnewood, Pennsylvania
- A Trial to Assess Consumer Self-Selection and Use of Gabapentin for Occasional Sleeplessness in an Over-the-Counter EnvironmentPivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT00659100 · 1,254 participants · Start Aug 2006
Drug: Gabapentin · For: Transient Insomnia
Sites: Anaheim, California; Bonita, California; Fallbrook, California · 35 sites in all
- A Study of Single-Dose Gabapentin in Transient Insomnia Induced by a Sleep Phase AdvancePivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT00667108 · 784 participants · Start Oct 2004
Drug: Gabapentin; Gabapentin and 1 more · For: Transient Insomnia
Sites: Anaheim, California; San Diego, California; Orlando, Florida · 8 sites in all
- A Study of Single-Dose Gabapentin in Subjects With Transient Insomnia Induced by a Sleep Phase AdvancePivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT00666939 · 773 participants · Start Oct 2004
Drug: Gabapentin; Gabapentin and 1 more · For: Transient Insomnia
Sites: San Diego, California; Ocala, Florida; Atlanta, Georgia · 10 sites in all
- Clinical Trial of Gabapentin to Decrease Postoperative Delirium and PainPivotal-lookingCompleted
University of California, San FranciscoAcademic, hospital or other
NCT00221338 · 750 participants · Start Jan 2006 · Primary completion Jan 2014
Drug: Gabapentin · For: Postoperative Delirium; Postoperative Pain; Opioid Use and 1 more
Sites: San Francisco, California
- Does Gabapentin and Lamotriginel Have Significantly Fewer Side-effects While Providing Equal or Better Seizure Control Than the Current Drug Choice, Carbamazepine, for the Treatment of Seizures in the Elderly.Pivotal-lookingCompleted
US Department of Veterans AffairsFederal agency
NCT00007670 · 720 participants · Start Jan 1998
Drug: Carbamazepine; Gabapentin and 1 more · For: Seizures
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 20 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- toxicity to various agents594
- completed suicide277
- drug ineffective217
- off label use187
- drug abuse138
- dizziness126
- somnolence125
- nausea122
- insomnia116
- cardio-respiratory arrest110
- headache110
- fatigue99
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2011 | 32 |
| 2012 | 104 |
| 2013 | 59 |
| 2014 | 35 |
| 2015 | 92 |
| 2016 | 206 |
| 2017 | 340 |
| 2018 | 352 |
| 2019 | 442 |
| 2020 | 308 |
| 2021 | 212 |
| 2022 | 293 |
| 2023 | 119 |
| 2024 | 89 |
| 2025 | 100 |
| 2026 | 61 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Horizant (Gabapentin Enacarbil)
2024 spending
$31.8M
Beneficiaries
5,984
28,883 claims
Per beneficiary
$5,320
$16.69 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $29,899,246 |
| 2021 | $32,575,765 |
| 2022 | $33,507,494 |
| 2023 | $32,997,342 |
| 2024 | $31,837,117 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A phase 2a, randomized, crossover trial of gabapentin enacarbil for the treatment of postherpetic neuralgia in gabapentin inadequate responders.
Harden RN, Freeman R, Rainka M, et al. · Pain Med 2013 · Clinical Trial, Phase II, Multicenter Study
- Impact of Data Imputation Methodology on Pain Assessment over 24 Hours in a Randomized, Placebo-Controlled Study of Gabapentin Enacarbil in Patients with Neuropathic Pain Associated with Postherpetic Neuralgia.
Calkins AM, Gudin J, Gidal B, et al. · Pain Med 2016 · Clinical Trial, Phase II, Randomized Controlled Trial
- Randomized, double-blind, placebo-controlled, phase II trial of gabapentin enacarbil for migraine prophylaxis.
Silberstein S, Goode-Sellers S, Twomey C, et al. · Cephalalgia 2013 · Clinical Trial, Phase II, Randomized Controlled Trial
- Placebo and nocebo responses in gabapentin enacarbil and pregabalin trials for restless legs syndrome: time-course model-based network meta-analysis and meta-analysis of proportions.
Iftikhar IH, Lacki OA, Albisher E, et al. · Sleep Breath 2026 · Network Meta-Analysis, Review
- A randomized, controlled trial of gabapentin enacarbil in subjects with neuropathic pain associated with diabetic peripheral neuropathy.
Rauck R, Makumi CW, Schwartz S, et al. · Pain Pract 2013 · Multicenter Study, Randomized Controlled Trial
- Effect of Gabapentin Enacarbil on Individual Items of the International Restless Legs Study Group Rating Scale and Post-sleep Questionnaire in Adults with Moderate-to-Severe Primary Restless Legs Syndrome: Pooled Analysis of 3 Randomized Trials.
Ahmed M, Hays R, Steven Poceta J, et al. · Clin Ther 2016 · Meta-Analysis
Sponsor: Azurity
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.